INCY
NASDAQIncyte Corp.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
Price$117.23-1.45 (-1.22%)
01:30 PM07:45 PM
News · 26 weeks113-5%
2026-01-182026-07-12
Mix6790d
- Insider30(45%)
- Other22(33%)
- SEC Filings9(13%)
- Earnings3(4%)
- Analyst2(3%)
- Leadership1(1%)
Latest news
25 items- PRIncyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat CancersRapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (NASDAQ:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madr
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 22,919 shares, decreasing direct ownership by 10% to 217,929 units (SEC Form 4) (tax withholding)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 1,949 shares, decreasing direct ownership by 3% to 57,712 units (SEC Form 4) (tax liability)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPrincipal Accounting Officer Tray Thomas covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 9% to 18,865 units (SEC Form 4) to cover withholding tax4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERCMO & Head of Late-Stage Dev. Stein Steven H sold $3,192,193 worth of shares (28,237 units at $113.05) and covered exercise/tax liability with 24,918 shares, decreasing direct ownership by 70% to 22,995 units (SEC Form 4) (for tax liability)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP, Head of U.S. Commercial Issa Mohamed Khairie covered exercise/tax liability with 1,099 shares, decreasing direct ownership by 2% to 65,033 units (SEC Form 4) to satisfy withholding tax4 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study - Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling Incyte (NASDAQ:INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for pa
- PRIncyte to Report Second Quarter Financial ResultsIncyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759527 If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-
- INSIDERChief Executive Officer Meury William covered exercise/tax liability with 4,779 shares, decreasing direct ownership by 3% to 156,322 units (SEC Form 4) (withholding tax)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 350 shares, decreasing direct ownership by 0.58% to 59,661 units (SEC Form 4) to cover taxes4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPrincipal Accounting Officer Tray Thomas covered exercise/tax liability with 477 shares, decreasing direct ownership by 2% to 20,655 units (SEC Form 4) to satisfy withholding obligation4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERCMO & Head of Late-Stage Dev. Stein Steven H covered exercise/tax liability with 2,177 shares, decreasing direct ownership by 3% to 76,150 units (SEC Form 4) to cover withholding tax4 - INCYTE CORP (0000879169) (Issuer)
- SECIncyte Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - INCYTE CORP (0000879169) (Filer)
- PRIncyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioAcquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline Incyte (NASDAQ:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder, to Incyte’s hematology portfolio. "With the acquisition complete, VGA039 adds one of the most promising late-stage hematology assets in development to our portfolio. As a potential first-in-class therapy
- INSIDERDirector Baker Bros. Advisors Lp was granted 800 shares (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Clancy Paul J was granted 252 shares, increasing direct ownership by 0.99% to 25,635 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Harrigan Edmund was granted 255 shares, increasing direct ownership by 1% to 23,019 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- PRStar Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 CongressStar Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming oral presentation of complete safety and efficacy data on all patients from its Phase 1/2 multidose study of VGA039 for von Willebrand disease (VWD), along with additional presentations on the program, at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress), being held July 11-15, 2026, in Paris, France. VGA039 is an investigational monoclonal antibody therapy designed to modulate Protein S to improve hemostasis and improve the body’s ability to c
- PRIncyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic DermatitisIf approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failed AD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2 Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (NASDAQ:INCY)
- ANALYSTIncyte upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Incyte from Underperform to Market Perform and set a new price target of $94.00
- SECIncyte Corp. filed SEC Form 8-K: Other Events8-K - INCYTE CORP (0000879169) (Filer)
- PRIncyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). "This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. "We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer." DLBCL is the most common subtype of non-Hodgkin lymphoma and is
- PRMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-
- PRIncyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential ThrombocythemiaIn myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib In essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks) Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential fo
- PRResults from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed across prespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global re
INCY FAQ
6 questionsWhat does Incyte Corp. do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial...Where does INCY stock trade?
Incyte Corp. (INCY) is listed on NASDAQ.What sector and industry is INCY in?
Incyte Corp. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.What are analysts saying about INCY?
Incyte Corp. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform on 2026-06-22.What companies are similar to INCY?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc), CRL (Charles River Laboratories International Inc.). Compare INCY side-by-side with any of them on Quantisnow.How can I track INCY on Quantisnow?
Quantisnow aggregates Incyte Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCY to receive live email and push alerts on every new disclosure.